Morgan Stanley lowered the firm’s price target on Personalis (PSNL) to $10 from $11 and keeps an Equal Weight rating on the shares. The firm updated estimates to reflect higher 2026 net loss guidance and higher opex in outer years.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis: Strong MRD Growth Prospects Offset by Weak 2026 Outlook and Margin Pressure, Justifying Hold Rating
- Personalis Bets on Scale Despite Near-Term Losses
- Accelerated MRD Expansion Positions Personalis for Long‑Term Growth Despite Near‑Term Margin Pressure
- Accelerating MRD Momentum and Reimbursement Tailwinds Support Buy Rating on Personalis
- Personalis sees FY26 revenue $78M-$80M, consensus $81.7M